A sensitive high-performance liquid chromatographic (HPLC) assay of the antineoplastic agent VP 16-213 (etoposide) in plasma is described. The system discriminates between the parent compound and possible metabolites, including the aglycone and the cis isomer. After extraction with 1,2-dichloroethane the drugs are chromatographed on a reversed-phase phenyl column with amperometric detection. Quantitative response is linear up to 250 ng/ml for 1 ml human plasma and up to 40.0 μg/ml for 0.1 ml human plasma. The detection limit is ca 2 ng/ml in plasma. Preliminary pharmacokinetic results show that the sensitivity and selectivity of the assay are adequate to establish plasma concentrations over 8-12 half-lives during elimination of the drug.
|Original language||English (US)|
|Number of pages||9|
|Journal||Journal of Pharmaceutical and Biomedical Analysis|
|State||Published - 1983|
- anti-tumour agents
- electrochemical chromatographic detection.
- High-performance liquid chromatography
ASJC Scopus subject areas
- Analytical Chemistry
- Pharmaceutical Science